Artificial intelligence is not just a buzzword; it's actively revolutionizing drug development, according to AstraZeneca CEO Pascal Soriot. He asserts that AI tools are empowering pharmaceutical companies to accelerate the creation of new medicines, pinpoint promising drug targets with greater accuracy, and significantly enhance the likelihood of success in high-stakes clinical trials.
Speaking on CNBC's "Mad Money," Soriot highlighted AI's immense value in boosting productivity within the industry. "In the way you design a new medicine, a new drug, you can actually do it faster, do it smarter," he explained.
These insights come amidst growing investor scrutiny regarding the tangible returns on substantial AI investments, particularly in sectors like healthcare. Soriot emphasized that AstraZeneca is already witnessing concrete applications of AI across its drug discovery and development pipeline. From identifying novel therapeutic targets to refining the molecular design of potential drugs, AI is proving indispensable.
"You can come up with new targets, but also you can optimize your molecule [and] remove what you think is going to be potential side effects from the molecule, and AI helps you do this," Soriot added.
AstraZeneca is leveraging AI through strategic partnerships, including collaborations with Tempus AI and Pathos. These alliances are crucial for making more informed decisions about which compounds to advance through the rigorous development process. Soriot specifically mentioned their work with Tempus AI, where advanced AI models analyze comprehensive datasets—combining clinical and laboratory information—to predict the probability of success for critical Phase 3 trials.
The financial implications are staggering. "We spend $300 million, $400 million, $500 million on a trial," Soriot revealed. "If you increase the probability of success, the productivity improvement is enormous." This highlights how AI is not just enhancing scientific discovery but also offering substantial economic advantages by mitigating the colossal costs associated with failed drug trials.
